Literature DB >> 35213002

Analysis of the Sphingolipidome in NAFLD.

David Montefusco1, Johana Lambert2, Andrea Anderson3, Jeremy Allegood2, L Ashley Cowart2.   

Abstract

The relationship between sphingolipid levels and NAFLD pathology has been recognized for some time. Numerous studies using pharmacological and genetic approaches in vitro and in animal models of NAFLD have demonstrated that modifications to sphingolipid metabolism can attenuate various facets of NAFLD pathology. However, a more precise understanding of the role of sphingolipids and NAFLD pathology is essential to creating therapeutics that target this pathway. This chapter touches on the scale and variety of sphingolipid metabolites at play in NAFLD, which vary widely in their chemical structures and biological functions. With advances in liquid chromatography and tandem mass spectrometry approaches, each of thousands of individual sphingolipid species and sphingolipid metabolites can be identified and precisely quantified. These approaches are beginning to reveal specific sub-classes and species of sphingolipids that change in NAFLD, and as such, enzymes that generate them can be identified and potentially serve as therapeutic targets. Advances in lipidomics technology have been, and will continue to be, critical to these gains in our understanding of NAFLD.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Alcoholic fatty liver disease; Ceramide; Lipid; Lipidomics; Metabolic syndrome; NAFLD; NASH; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Sphingoid; Sphingolipids; Sphingosine; Sphingosine-1-phosphate

Mesh:

Substances:

Year:  2022        PMID: 35213002      PMCID: PMC9159091          DOI: 10.1007/978-1-0716-2128-8_22

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  39 in total

1.  FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice.

Authors:  Timothy D Rohrbach; Amon Asgharpour; Melissa A Maczis; David Montefusco; L Ashley Cowart; Pierre Bedossa; Arun J Sanyal; Sarah Spiegel
Journal:  J Lipid Res       Date:  2019-05-20       Impact factor: 5.922

Review 2.  An overview of sphingolipid metabolism: from synthesis to breakdown.

Authors:  Christopher R Gault; Lina M Obeid; Yusuf A Hannun
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

3.  mTORC2 Promotes Tumorigenesis via Lipid Synthesis.

Authors:  Yakir Guri; Marco Colombi; Eva Dazert; Sravanth K Hindupur; Jason Roszik; Suzette Moes; Paul Jenoe; Markus H Heim; Isabelle Riezman; Howard Riezman; Michael N Hall
Journal:  Cancer Cell       Date:  2017-12-11       Impact factor: 31.743

4.  CerS2 haploinsufficiency inhibits β-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance.

Authors:  Suryaprakash Raichur; Siew Tein Wang; Puck Wee Chan; Ying Li; Jianhong Ching; Bhagirath Chaurasia; Bghagirath Chaurasia; Shaillay Dogra; Miina K Öhman; Kosuke Takeda; Shigeki Sugii; Yael Pewzner-Jung; Anthony H Futerman; Scott A Summers
Journal:  Cell Metab       Date:  2014-10-07       Impact factor: 27.287

5.  Dihydrosphingosine 1-phosphate has a potent antifibrotic effect in scleroderma fibroblasts via normalization of phosphatase and tensin homolog levels.

Authors:  Shizhong Bu; Yoshihide Asano; Andreea Bujor; Kristin Highland; Faye Hant; Maria Trojanowska
Journal:  Arthritis Rheum       Date:  2010-07

6.  Targeted Induction of Ceramide Degradation Leads to Improved Systemic Metabolism and Reduced Hepatic Steatosis.

Authors:  Jonathan Y Xia; William L Holland; Christine M Kusminski; Kai Sun; Ankit X Sharma; Mackenzie J Pearson; Angelika J Sifuentes; Jeffrey G McDonald; Ruth Gordillo; Philipp E Scherer
Journal:  Cell Metab       Date:  2015-07-16       Impact factor: 27.287

7.  Hepatic fatty acid uptake is regulated by the sphingolipid acyl chain length.

Authors:  Woo-Jae Park; Joo-Won Park; Alfred H Merrill; Judith Storch; Yael Pewzner-Jung; Anthony H Futerman
Journal:  Biochim Biophys Acta       Date:  2014-12

8.  IRE1A Stimulates Hepatocyte-Derived Extracellular Vesicles That Promote Inflammation in Mice With Steatohepatitis.

Authors:  Debanjali Dasgupta; Yasuhiko Nakao; Amy S Mauer; Jill M Thompson; Tejasav S Sehrawat; Chieh-Yu Liao; Anuradha Krishnan; Fabrice Lucien; Qianqian Guo; Mengfei Liu; Fei Xue; Masanori Fukushima; Tomohiro Katsumi; Aditya Bansal; Mukesh K Pandey; Jessica L Maiers; Timothy DeGrado; Samar H Ibrahim; Alexander Revzin; Kevin D Pavelko; Michael A Barry; Randal J Kaufman; Harmeet Malhi
Journal:  Gastroenterology       Date:  2020-06-20       Impact factor: 22.682

9.  Inhibiting Ceramide Synthesis Attenuates Hepatic Steatosis and Fibrosis in Rats With Non-alcoholic Fatty Liver Disease.

Authors:  Meng Jiang; Chun Li; Qiaoshu Liu; Aimin Wang; Minxiang Lei
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-26       Impact factor: 5.555

10.  Correction: Targeting alkaline ceramidase 3 alleviates the severity of nonalcoholic steatohepatitis by reducing oxidative stress.

Authors:  Kai Wang; Chuanjiang Li; Xinxin Lin; Hang Sun; Ruijuan Xu; Qingping Li; Yiran Wei; Yiyi Li; Jianping Qian; Cuiting Liu; Qifan Zhang; Sheng Yu; Zhonglin Cui; Xixin Huang; Bili Zhu; Jie Zhou; Cungui Mao
Journal:  Cell Death Dis       Date:  2020-03-17       Impact factor: 8.469

View more
  1 in total

1.  Multi-Omics Characterizes the Effects and Mechanisms of CD1d in Nonalcoholic Fatty Liver Disease Development.

Authors:  Qiuxian Zheng; Chen Xue; Xinyu Gu; Dandan Shan; Qingfei Chu; Jing Wang; Haihong Zhu; Zhi Chen
Journal:  Front Cell Dev Biol       Date:  2022-04-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.